KR20210104952A - Functional health food for defecaation inducement and diet - Google Patents
Functional health food for defecaation inducement and diet Download PDFInfo
- Publication number
- KR20210104952A KR20210104952A KR1020200018903A KR20200018903A KR20210104952A KR 20210104952 A KR20210104952 A KR 20210104952A KR 1020200018903 A KR1020200018903 A KR 1020200018903A KR 20200018903 A KR20200018903 A KR 20200018903A KR 20210104952 A KR20210104952 A KR 20210104952A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- functional food
- health functional
- diet
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title claims abstract description 14
- 230000037213 diet Effects 0.000 title claims abstract description 13
- 235000013402 health food Nutrition 0.000 title 1
- 235000013376 functional food Nutrition 0.000 claims abstract description 33
- 230000036541 health Effects 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 22
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000533293 Sesbania emerus Species 0.000 claims abstract description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 229940069765 bean extract Drugs 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 10
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 10
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 10
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 10
- 239000001259 polydextrose Substances 0.000 claims abstract description 10
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 10
- 229940035035 polydextrose Drugs 0.000 claims abstract description 10
- 229930091371 Fructose Natural products 0.000 claims abstract description 9
- 239000005715 Fructose Substances 0.000 claims abstract description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 9
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 9
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 9
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract description 8
- 230000013872 defecation Effects 0.000 claims description 14
- 230000006698 induction Effects 0.000 claims description 9
- 241001474374 Blennius Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 abstract description 23
- 210000001596 intra-abdominal fat Anatomy 0.000 abstract description 7
- 235000019640 taste Nutrition 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 235000014633 carbohydrates Nutrition 0.000 abstract description 4
- 230000003187 abdominal effect Effects 0.000 abstract description 2
- 210000000579 abdominal fat Anatomy 0.000 abstract description 2
- 239000003925 fat Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 206010010774 Constipation Diseases 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 241000220225 Malus Species 0.000 description 6
- 235000011430 Malus pumila Nutrition 0.000 description 6
- 235000015103 Malus silvestris Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000593508 Garcinia Species 0.000 description 2
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 244000094788 Dombeya wallichii Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036391 Genetic obesity Diseases 0.000 description 1
- 244000037471 Gordonia integerrima Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241001573298 Meliosma oldhamii Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 241001149258 Sporobolus alterniflorus Species 0.000 description 1
- 241000544066 Stevia Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- -1 citric acid Chemical class 0.000 description 1
- 239000008373 coffee flavor Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000021197 fiber intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000037493 inherited obesity Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2108—Caffeine, coffee extract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2118—Garcinia cambogia, hydroxycitric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/24—Non-sugar sweeteners
- A23V2250/262—Stevioside
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/61—Glucose, Dextrose
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 건강기능식품에 관한 것으로, 더욱 상세하게는 지방 합성을 억제하여 체지방을 감소시키고, 배변을 유도하여 변비를 개선하는 배변유도 및 다이어트용 건강기능식품에 관한 것이다. The present invention relates to a health functional food, and more particularly, to a health functional food for defecation induction and diet, which reduces body fat by inhibiting fat synthesis, and improves constipation by inducing defecation.
근래 식생활의 서구화 및 인스턴트화로 열량의 섭취는 늘어난 반면 섬유소 섭취의 감소와 운동량의 저하로 인해 종래 서양에서 많이 발생하던 병이 국내에서도 점차 증가하고 있다.In recent years, calorie intake has increased due to the westernization and instantiation of dietary life, but due to a decrease in fiber intake and a decrease in exercise amount, the disease that has occurred in the West is gradually increasing in Korea.
그 중 비만은 신체의 에너지 섭취량이 소비량을 초과하여 결국 과체중에 이르게 되어 발현되는 만성적인 신체 상태를 나타내는 것으로, 과거 비만에 대한 의학적 소견은 과식이나 게으름 등의 결과로서 발생하는 생활습관의 질병으로 인식하였으나, 현재에는 이러한 비만을 방치할 경우에 중대한 질병을 동반할 수 있는 의학적 질병으로 인식하고 있다.Among them, obesity refers to a chronic physical condition that is expressed as the body's energy intake exceeds its consumption and eventually leads to overweight. However, it is currently recognized as a medical disease that can accompany serious diseases if left unattended.
비만의 원인은 명확하게 규명되지 않았으나, 신체의 체중조절 기능의 이상, 유전적 비만성향, 나이, 사회, 환경적 영향 및 과도한 지방섭취, 그리고 풍요로운 산업사회로 인한 낮은 육체활동 등이 지목되고 있다.Although the cause of obesity is not clearly identified, abnormalities in the body's weight control function, genetic obesity tendencies, age, social and environmental influences, excessive fat intake, and low physical activity due to an affluent industrial society are pointed out.
비만은 흡연 다음으로 질병 이외의 사망을 유발하는 두 번째 인자이다. 비만은 대사 증후군의 직접적인 원인이며 암, 심장병, 당뇨, 고혈압 등 다른 치명적인 질병들을 초래한다. 실제로 비만인은 정상인보다 사망률이 28% 높고, 일반인에 비해 고혈압은 56배, 고지혈증은 21배, 당뇨병은 29배나 발병 위험이 크다.Obesity is the second leading cause of non-morbid mortality after smoking. Obesity is a direct cause of metabolic syndrome and leads to other fatal diseases such as cancer, heart disease, diabetes and high blood pressure. In fact, obese people have a 28% higher mortality rate than normal people, and compared to the general population, high blood pressure is 56 times, hyperlipidemia is 21 times, and diabetes is 29 times higher.
연령에 관계없이 비만 치료의 기본 원칙은 식이 요법, 운동 요법, 행동조절요법과 그리고 약물치료법이 있다.Regardless of age, the basic principles of obesity treatment include diet, exercise, behavioral control, and drug therapy.
현재 국내에서 인정되는 비만치료제는 식욕억제제인 시부트라민과 지방흡수억제제 올리스타트가 전부이지만, 항 비만 효과를 가지는 약물을 작용기전에 따라 크게 분류하면 식욕억제제, 소화억제제, 열대사촉진제, 및 호르몬과 펩타이드 조절로 구분할 수 있다.Currently, only the appetite suppressant sibutramine and the fat absorption inhibitor orlistat are recognized in Korea for the treatment of obesity. can be distinguished as
그러나 이러한 비만 치료제들은 식욕억제를 주 목적으로 하고 있는바, 장운동을 활발히 할 수 있는 영양분의 섭취가 부족하여 대부분의 비만 치료제를 섭취한 소비자들의 경우에는 변비로 고생하는 경우가 많은 것으로 알려져 있다.However, these anti-obesity drugs are mainly aimed at suppressing appetite, and it is known that consumers who have consumed most anti-obesity drugs suffer from constipation due to insufficient intake of nutrients that can actively promote bowel movements.
일반적으로 사람이 음식을 섭취 후 음식의 영양성분이 인체 내부의 기관에 의해 필요한 곳으로 이동되면 영양성분이 빠진 음식물의 찌꺼기가 보통 12~72시간 후에 인체 외부로 대변의 형태로 배설되는 것이 정상적인 상태이다. 그러나 상기의 대변이 어떠한 이유로 인해 인체 외부로 배출되지 못하고, 결장 안에 오랜 시간 머물러 있게 되는 경우가 있는데 이러한 것을 변비라고 한다.In general, after a person consumes food, when the nutrients of the food are moved to the required place by the internal organs of the human body, it is normal for the food residues without nutrients to be excreted in the form of feces outside the human body after 12 to 72 hours. am. However, the feces are not discharged to the outside of the body for some reason, and there are cases where they remain in the colon for a long time, which is called constipation.
변비가 생기면 대장으로 흡수된 수분이 혈액으로 되돌려 보내지는 가운데 대장의 기능이 떨어져 수분이 과다로 제거되어 몸에 해로운 물질을 체외로 배출시키지 못하고 신진대사가 제대로 이루어지지 않아 장내에 숙변을 비롯하여 여러 가지 증상이 나타난다. 예를 들면 만성두통을 비롯한 호소하는 경우가 있는데 이는 장에서 발생한 유독가스가 혈액을 타고 뇌 속으로 들어가 뇌기능을 어지럽히고 이 가스는 각종 기관을 압박하며 피의 흐름이 나빠지면서 충혈과 염증을 일으키고 체내 산소와 영양소 흡수가 이루어지지 않아 각종 질병을 유발시킨다.When constipation occurs, the water absorbed into the large intestine is returned to the blood, and the function of the large intestine is lowered and the water is removed excessively. symptoms appear. For example, there are cases of complaints such as chronic headaches, which are caused by toxic gas from the intestine entering the brain through the blood and disturbing brain functions. and nutrients are not absorbed, leading to various diseases.
이와 같이 대장에서 만들어지는 유해가스는 간에서 해독되지만 간이 건강하지 못하거나 유해가스의 발생이 과도한 경우 해독되지 못한 유해가스는 온몸의 기능을 저하시켜 신진대사가 제대로 이루어지지 않게 되어 궤양성 대장염, 크론병, 피부근염, 신장질환 등의 질병에 노출되기 쉽다.In this way, the harmful gas produced in the large intestine is detoxified in the liver, but if the liver is not healthy or the generation of harmful gas is excessive, the undetoxified harmful gas lowers the function of the body and the metabolism is not performed properly. It is easy to be exposed to diseases such as disease, dermatomyositis, and kidney disease.
또한, 장내 유익균이 활성화되지 못한 경우 세로토닌 합성대사가 이루어지지 못해 스트레스 지수가 상승하고, 우울증 및 분노조절장애와 같은 정신질환이 발생한다고 발표된 바 있다.In addition, it has been announced that when beneficial intestinal bacteria are not activated, serotonin synthesis metabolism is not achieved, which leads to an increase in the stress index, and the occurrence of mental disorders such as depression and anger control disorder.
이에, 종래에는 변비가 발생하면 치료를 위해 치료제를 복용하는데, 이러한 치료는 예방적인 활동이 아니고 대장에 이상이 생긴 후에야 사용하는 문제점이 있으며, 특히 최근에는 장내 유익균 중 유산균을 혼합한 변비 치료제들이 많이 개발되고 있는데, 실질적으로 이러한 유산균들이 장내 유익세균총에 잘 안착하지 못하여 변비 치료효능이나 더 나아가 비만개선 효과에 대해서는 그다지 높지 않은 문제점이 있다.Therefore, in the prior art, when constipation occurs, a therapeutic agent is taken for treatment, but this treatment is not a preventive activity, and there is a problem that it is used only after an abnormality occurs in the large intestine. In fact, these lactic acid bacteria do not settle well in the beneficial intestinal flora, so there is a problem that the effect of treating constipation or improving obesity is not very high.
따라서, 비만의 개선 및 변비의 개선 효과가 우수하면서도, 영양 생리학적으로 부작용이 없는 건강보조식품이 요구되고 있다.Therefore, there is a demand for a health supplement that is excellent in the improvement of obesity and constipation, and has no nutritional and physiological side effects.
따라서, 본 발명의 목적은 탄수화물이 지방으로 합성되는 것을 억제하여 체지방 감소에 도움을 주고, 장 내용물의 부피를 증가시켜 배변을 유도하는 배변유도 및 다이어트용 건강기능식품을 제공하는 데 있다. Accordingly, an object of the present invention is to provide a health functional food for bowel induction and diet that helps to reduce body fat by inhibiting the synthesis of carbohydrates into fat and induces bowel movements by increasing the volume of intestinal contents.
본 발명의 다른 목적은 천연물을 원료로 함으로써 생리학적 부작용이 없고, 누구나 좋아하는 커피맛을 첨가하여 복용이 용이한 배변유도 및 다이어트용 건강기능식품을 제공하는 데 있다. Another object of the present invention is to provide a health functional food for inducing bowel movement and diet that has no physiological side effects by using a natural product as a raw material, and is easy to take by adding a coffee flavor that anyone likes.
상기한 목적을 달성하기 위한 본 발명의 배변유도 및 다이어트용 건강기능식품은, 난소화성 말토덱스트린, 가르시니아 캄보지아 추출물, 원두커피분말, 폴리덱스트로스, 결정포도당, 결정과당, 이산화규소, 효소처리스테비아, 그린커피빈 추출물 및 마테 추출물을 더 포함하는 것을 특징으로 한다.The health functional food for bowel induction and diet of the present invention for achieving the above object is indigestible maltodextrin, garcinia cambogia extract, coffee bean powder, polydextrose, crystalline glucose, fructose, silicon dioxide, enzyme-treated stevia, green coffee It is characterized in that it further comprises a bean extract and mate extract.
상기 가르시니아 캄보지아 추출물 10~20중량%, 원두커피분말 15~25중량%, 폴리덱스트로스 8~12중량%, 결정포도당 8~12중량%, 결정과당 3~7중량%, 이산화규소 1.5~2중량%, 효소처리스테비아 0.1~1중량%, 그린커피빈 추출물 0.01~0.5중량%, 마테 추출물 0.01~0.5중량% 및 잔부의 난소화성 말토덱스트린을 포함하는 것을 특징으로 한다.The garcinia cambogia extract 10-20 wt%, coffee bean powder 15-25 wt%, polydextrose 8-12 wt%, crystalline glucose 8-12 wt%, fructose 3-7 wt%, silicon dioxide 1.5-2 wt%, It is characterized in that it contains 0.1 to 1% by weight of enzyme-treated stevia, 0.01 to 0.5% by weight of green coffee bean extract, 0.01 to 0.5% by weight of mate extract, and the remainder indigestible maltodextrin.
갯끈풀 추출물 0.1~1중량% 및 루비에스 사과껍질 추출물 0.1~1중량%를 더 포함하는 것을 특징으로 한다. It is characterized in that it further comprises 0.1 to 1% by weight of seaweed extract and 0.1 to 1% by weight of rubies apple peel extract.
합다리나무 추출물 0.1~1중량%를 더 포함하는 것을 특징으로 한다.It is characterized in that it further comprises 0.1 to 1% by weight of the extract of Hapdari tree.
본 발명에 의한 배변유도 및 다이어트용 건강기능식품에 따르면, 탄수화물이 지방으로 합성되는 것을 억제하며, 복부 및 내장 지방을 효과적으로 제거하여 체지방 감소에 도움을 주고, 원활한 배변유도가 가능하며, 분말형태로 복용이 간편하고, 누구나 좋아하는 커피맛으로 인해 복용이 용이하다는 장점이 있다.According to the health functional food for defecation induction and diet according to the present invention, it suppresses the synthesis of carbohydrates into fat, helps to reduce body fat by effectively removing abdominal and visceral fat, and enables smooth bowel movements, and is available in powder form. It is easy to take and has the advantage of being easy to take because of the coffee taste that everyone likes.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서 상기 건강기능식품이란, 배변 유도 및 체지방 감소를 돕는 기능성을 갖는 식품을 의미하는 것임을 밝혀둔다In the present invention, it is revealed that the health functional food means a food having a function of helping to induce bowel movements and reduce body fat.
본 발명에 의한 건강기능식품은, 각 성분들의 상호작용을 통해 체지방 감소, 신진대사 강화, 배변유도 등의 효과를 극대화하는 것으로, 화학적 약제가 아닌 천연원료만을 이용하여 생리학적으로 부작용이 없다는 데 가장 큰 특징이 있다. 또한, 분말 형태로 그 섭취가 용이함은 물론, 커피맛으로 인해 접근이 용이하며, 단맛이 강화되어 관능적 기호도 역시 우수하다는 데 특징이 있다.The health functional food according to the present invention maximizes the effects of reducing body fat, enhancing metabolism, inducing bowel movements, etc. through the interaction of each component. It has great features. In addition, it is characterized in that it is easy to consume in the form of a powder, and it is easy to access due to the taste of coffee, and the sensual preference is also excellent because of the enhanced sweetness.
이러한 본 발명의 배변유도 및 다이어트용 건강기능식품은, 난소화성 말토덱스트린, 가르시니아 캄보지아 추출물, 원두커피분말, 폴리덱스트로스, 결정포도당, 결정과당, 이산화규소, 효소처리스테비아, 그린커피빈 추출물 및 마테 추출물을 포함하는 것을 특징으로 한다.The health functional food for bowel induction and diet of the present invention contains indigestible maltodextrin, garcinia cambogia extract, coffee bean powder, polydextrose, crystalline glucose, crystalline fructose, silicon dioxide, enzyme-treated stevia, green coffee bean extract and mate extract. characterized by including.
먼저, 상기 난소화성 말토덱스트린(Indigestible maltodextrin)은 배변 활동 원활, 식후 혈당 상승 억제 및 혈중 중성지질 개선의 기능성이 공식 인정되어 있는 원료로서, 옥수수 전분을 가열하여 얻은 배소덱스트린을 α-아밀라제(α-amylase, Bacillus subtilis 또는 Bacillus licheniformis 유래) 및 아밀로글루코시다제(amyloglucosidase, Aspergilus niger 유래)로 효소분해하고 정제한 것 중 난소화성 성분을 분획하여 식용에 접합하도록 한 것을 말한다. 액상이 아닌 경우에는 식이섬유를 85% 이상하고 있어야 하나, 액상인 경우에는 58% 이상 함유하고 있어야 한다. 본 발명에서는 원활한 섭취를 위하여 분말 상을 이용하는 것으로, 식이섬유의 보수력에 의해 변 표면과 장내에 점성이 높은 겔을 형성하면서 장 내용물의 부피를 증가시켜 배변활동을 용이하게 하는 역할을 한다. First, the indigestible maltodextrin is a raw material officially recognized for its functions of smooth bowel movements, suppression of postprandial blood glucose rise, and improvement of blood triglycerides. Amylase, Bacillus subtilis or Bacillus licheniformis) and amyloglucosidase (amyloglucosidase, derived from Aspergilus niger) are enzymatically decomposed and purified by fractionation of indigestible components to make them suitable for consumption. If it is not liquid, it should contain 85% or more of dietary fiber, but if it is liquid, it should contain more than 58%. In the present invention, powdered form is used for smooth intake, and it serves to increase the volume of intestinal contents while forming a highly viscous gel on the surface of the stool and in the intestine due to the water holding capacity of dietary fiber, thereby facilitating defecation activity.
상기 난소화성 말토덱스트린은 본 발명의 건강기능식품 내 기타 성분을 제외한 잔부만큼 포함된다.The indigestible maltodextrin is included as much as the remainder excluding other ingredients in the health functional food of the present invention.
상기 가르시니아 캄보지아 추출물은 가르시니아 캄보지아(Garcinia cambogia) 열매의 껍질을 물로 추출하고, 이를 건조한 것으로, 주된 성분은 HCA(hydroxyl citric acid)이며, 체지방의 감소에 효과를 발휘한다. 상기 HCA는 탄수화물이 지방으로 전환될 때 사용되는 효소(ATP-citrate lyase)의 활성을 억제하여 체중과 체지방량을 감소시키는 것이다. 상기 가르시니아 캄보지아 추출물은 시판 상품 중 어떠한 것이라도 사용 가능한바, 시판상품은 상기 기능성분인 HCA의 함량은 약 60%로 표준화되어 있다. The Garcinia cambogia extract is obtained by extracting the bark of Garcinia cambogia fruit with water and drying it, and the main component is HCA (hydroxyl citric acid), which is effective in reducing body fat. The HCA reduces body weight and body fat by inhibiting the activity of an enzyme (ATP-citrate lyase) used when carbohydrates are converted into fat. The Garcinia cambogia extract can be used in any of the commercially available products, and the commercially available products have standardized the content of HCA, which is the functional ingredient, to about 60%.
상기 가르시니아 캄보지아 추출물은 본 발명의 건강기능식품 내 10~20중량%로 포함될 수 있는바, 그 함량이 10중량% 미만이면 체지방 감소의 효과가 미미하고, 20중량%를 초과할 경우 과량의 가르시니아 캄보지아 추출물이 간독성을 일으킬 우려가 있기 때문이다. 즉, 본 발명은 종래 가르시니아 캄보지아 추출물을 포함하는 건강기능식품에 비해 추출물의 함량을 낮추면서도, 체중감소 및 체지방 분해의 효과를 높일 수 있다는 데 특징이 있다.The garcinia cambogia extract may be included in 10 to 20% by weight in the health functional food of the present invention. If the content is less than 10% by weight, the effect of reducing body fat is insignificant, and when it exceeds 20% by weight, excess garcinia cambogia This is because the extract may cause hepatotoxicity. That is, the present invention is characterized in that it can increase the effect of weight loss and body fat decomposition while lowering the content of the extract compared to the health functional food containing the conventional Garcinia cambogia extract.
상기 원두커피분말은 건강기능식품의 풍미를 개선하기 위한 것으로, 대중적으로 누구나 좋아하는 커피맛을 느낄 수 있도록 하여 건강기능식품을 부담없이 섭취할 수 있도록 하는 성분이다. 또한, 체지방 분해를 촉진하는 역할도 하여, 가르시니아 캄보지아 추출물과 함께 체지방 감소를 돕는다.The coffee bean powder is intended to improve the flavor of health functional food, and is a component that allows the public to feel the coffee taste that everyone likes, so that the health functional food can be consumed without burden. In addition, it also plays a role in promoting body fat breakdown, helping to reduce body fat together with Garcinia cambogia extract.
상기 원두커피분말은 본 발명의 건강기능식품 내 15~25중량%로 포함될 수 있는바, 그 함량이 15중량% 미만이면 그 기능이 미미하고, 25중량%를 초과하면 과량이 되어 전체적인 기능성이 저하될 수 있기 때문이다.The coffee bean powder may be included in 15 to 25% by weight in the health functional food of the present invention. If the content is less than 15% by weight, the function is insignificant, and if it exceeds 25% by weight, it is excessive and the overall functionality is lowered. because it can be
상기 폴리덱스트로스는 구연산 등의 유기산을 사용하여 포도당과 솔비톨로부터 합성된 것으로, 평균 중합도가 12 정도가 되도록 제조된 것을 말하며, 식이섬유를 65% 이상 함유하고 있어야 기능성 원료로서 사용될 수 있다. 상기 폴리덱스트로스는 배변 활동을 원활히 해주는 역할을 하는 것으로, 상기 난소화성 말토덱스트린과의 상호작용을 통해 배변활동을 촉진하고, 변비를 개선해준다.The polydextrose is synthesized from glucose and sorbitol using organic acids, such as citric acid, and is prepared so that the average degree of polymerization is about 12, and it can be used as a functional raw material when it contains 65% or more of dietary fiber. The polydextrose serves to facilitate bowel movements, and through interaction with the indigestible maltodextrin, it promotes bowel movements and improves constipation.
상기 폴리덱스트로스는 본 발명의 건강기능식품 내 8~12중량%로 포함됨이 바람직한바, 그 함량이 너무 적거나 많으면 전체적인 기능성이 저하되기 때문이다. The polydextrose is preferably contained in an amount of 8 to 12% by weight in the health functional food of the present invention, because if the content is too small or too much, the overall functionality is reduced.
상기 결정포도당은 인체의 근성장을 돕는 것은 물론, 관능성을 개선해주는 것으로, 함수결정포도당은 물론, 무수결정포도당 등 그 종류와 무관하게 사용할 수 있다. 본 발명에서는 분말 형태의 것을 사용한다.The crystalline glucose not only helps the muscle growth of the human body, but also improves the sensuality, and can be used regardless of the type, such as hydrous crystalline glucose as well as anhydrous crystalline glucose. In the present invention, a powder form is used.
상기 결정포도당은 본 발명의 건강기능식품 내 8~12중량%로 포함됨이 바람직한바, 그 함량이 너무 적으면 관능성 개선의 효과가 미미하고, 과량이 되면 체지방 감소 효과가 떨어지기 때문이다. The crystalline glucose is preferably contained in an amount of 8 to 12% by weight in the health functional food of the present invention. If the content is too small, the effect of improving the sensory function is insignificant, and if it is excessive, the effect of reducing body fat is reduced.
상기 결정과당은 쓴맛을 없애고, 풍미 증진을 위해 사용되는 성분이다.The fructose crystal is a component used to remove bitterness and enhance flavor.
상기 결정과당은 본 발명의 건강기능식품 내 3~7중량%로 포함됨이 바람직한바, 그 함량이 너무 적으면 풍미 증진의 효과가 미미하고, 과량이 되면 체지방 감소 효과가 떨어지기 때문이다. The fructose crystals are preferably contained in 3 to 7% by weight in the health functional food of the present invention, because if the content is too small, the effect of enhancing the flavor is insignificant, and if the content is excessive, the effect of reducing body fat decreases.
상기 이산화규소는 고결을 방지하기 위해 사용되는 성분이다.The silicon dioxide is a component used to prevent caking.
상기 이산화규소는 본 발명의 건강기능식품 내 1.5~2중량%로 포함되는 것이 바람직한바, 그 함량이 너무 적으면 고결을 방지할 수 없고, 과량이 되더라도 더 이상의 증진된 효과를 기대할 수 없어 경제적이지 못하기 때문이다.The silicon dioxide is preferably contained in 1.5 to 2% by weight in the health functional food of the present invention, and if the content is too small, caking cannot be prevented, and even if it is excessive, no further enhanced effect can be expected, so it is not economical because you can't
상기 효소처리스테비아는 감미료로서 사용됨은 물론, 해독 작용, 장내 유산균 증가, 숙취 및 피부 개선의 역할을 한다. 아울러, 쓴맛을 완화시켜 전체적인 관능성을 개선해준다. The enzyme-treated stevia is used as a sweetener, as well as detoxifying, increasing intestinal lactic acid bacteria, hangover, and improving skin. In addition, it alleviates bitterness and improves overall sensuality.
상기 효소처리스테비아는 본 발명의 건강기능식품 내 0.1~1중량%로 포함됨이 바람직한바, 그 함량이 너무 적으면 그 기능이 미미하고, 과량이 되더라도 더 이상의 증진된 효과를 기대할 수 없어 경제적이지 못하기 때문이다.The enzyme-treated stevia is preferably contained in an amount of 0.1 to 1% by weight in the health functional food of the present invention. If the content is too small, the function is insignificant, and even if it is excessive, no further enhanced effect can be expected, so it is not economical. because it does
상기 그린커피빈 추출물은 식욕을 감소시키는 것은 물론, 콜레스테롤을 감소시켜주고, 지방 분해를 돕는 성분이다. 상기 그린커피빈 추출물은 그린커피빈을 물을 용매로 하여 추출하고 이를 건조하여 분말화한 것을 의미하는 것으로, 그 추출방법은 종래 게시된 천연물의 추출방법에 의하는 정도면 족하다.The green coffee bean extract is a component that not only reduces appetite, but also reduces cholesterol and helps in fat breakdown. The green coffee bean extract means that green coffee beans are extracted using water as a solvent, dried and powdered.
상기 그린커피빈 추출물은 본 발명의 건강기능식품 내 0.01~0.5중량%로 포함됨이 바람직한바, 그 함량이 너무 적으면 기능성이 저하되며, 과량이 되더라도 더 이상의 증진된 작용효과가 없으므로, 경제적이지 못하기 때문이다. The green coffee bean extract is preferably contained in an amount of 0.01 to 0.5% by weight in the health functional food of the present invention. If the content is too small, the functionality is reduced, and even if it is excessive, there is no further enhanced effect, so it is not economical. because it does
상기 마테 추출물은 마테나무의 잎을 따서 건조시킨 후 추출하여 분말화한 원료를 사용한다. 상기 마테 추출물에는 마테인(Mataine)이라는 성분이 함유되어 있어 체지방을 분해해주는 효과가 있으며, 식욕을 억제하는 기능도 있다. 아울러, 체중감량시 운동과 병행할 시 체내에 활성산소 공급을 높여 운동 시 피로도를 낮추며 에너지 소비를 높여 칼로리 소비를 증가시키는 작용도 한다.The mate extract uses a raw material powdered by extracting and drying the leaves of the mate tree. The mate extract contains a component called matein, which has an effect of decomposing body fat and also has a function of suppressing appetite. In addition, when weight loss is combined with exercise, it increases the supply of active oxygen to the body, thereby reducing fatigue during exercise and increasing energy consumption to increase calorie consumption.
상기 마테 추출물은 본 발명의 건강기능식픔 내 0.01~0.5중량%로 포함됨이 바람직한바, 그 함량이 너무 적으면 기능성이 저하되며, 과량이 되더라도 더 이상의 증진된 작용효과가 없으므로, 경제적이지 못하기 때문이다. The mate extract is preferably contained in 0.01 to 0.5% by weight in the health functional food of the present invention, and if the content is too small, the functionality is reduced, and even if it is excessive, there is no further enhanced effect, so it is not economical am.
상기와 같이 구성되는 본 발명의 건강기능식품은 그 성분이 모두 식품재료 및 식품으로 사용되는 것으로, 복용 또는 섭취시 인체에 대한 안전성이 우수하다. 그리고 분말 형태로 제형화된 것으로 설명하였지만, 통상의 방법을 통해 환, 정제 등의 형태로 제형화할 수 있음은 당연하다. The health functional food of the present invention constituted as described above has excellent safety for the human body when taken or ingested, since all of its components are used as food materials and food. And although it has been described as being formulated in powder form, it is natural that it can be formulated in the form of pills, tablets, etc. through a conventional method.
아울러, 본 발명의 건강기능식품은, 관능성이 우수하고, 배변 유도 및 체지방 감소 효과가 우수하다는 장점이 있다.In addition, the health functional food of the present invention has advantages in that it has excellent organoleptic properties, and has excellent effect of inducing defecation and reducing body fat.
본 발명의 건강기능식품은 성인 기준, 1회 약 4g을 1일 1~3회에 걸쳐 섭취할 수 있으나, 그 섭취량을 제한하는 것은 아니며, 물 200ml에 혼합하여 섭취할 수도 있으며, 그냥 섭취할 수도 있는 것으로, 그 섭취량, 섭취방법을 제한하지 않는다. The health functional food of the present invention can be consumed 1 to 3 times a day at about 4 g per adult basis, but the amount of intake is not limited, and it can be mixed with 200 ml of water and consumed. It does not limit the amount of intake or the method of intake.
또한, 상기 건강기능식품은 갯끈풀 추출물 0.1~1중량% 및 루비에스 사과껍질 추출물 0.1~1중량%를 더 포함할 수 있다.In addition, the health functional food may further include 0.1 to 1% by weight of the seaweed extract and 0.1 to 1% by weight of the rubies apple peel extract.
상기 갯끈풀(Spartina alterniflora)은 볏과 식물로서, 뿌리를 제외한 잎, 줄기, 줄기껍질, 가지, 가지껍질, 꽃 등의 지상부를 물 등의 용매로 추출하여 건조한 추출물을 더 포함할 경우, 우수한 항산화 활성 등으로 인해 체지방 감소 중 피부 탄력이 저하되는 것을 방지하는 역할을 한다. 또한, 식욕을 억제하는 역할도 한다.The seaweed (Spartina alterniflora) is a crested plant, and when the above-ground parts of leaves, stems, stem bark, branches, eggplant bark, flowers, etc., except for roots, are extracted with a solvent such as water, and further contains a dry extract, excellent antioxidant It plays a role in preventing deterioration of skin elasticity during body fat reduction due to activity, etc. It also acts as an appetite suppressant.
또한, 상기 루비에스(Rubies; Malus pumila Mill) 사과는 일본 품종인 '알프스오토메' 품종에 '산사'품종을 교배하여 육성한 신 육성 품종으로, 루비에스 사과의 껍질을 물 등의 용매로 추출하여 건조한 추출물을 더 포함할 경우, 우수한 항산화 활성 등으로 인해 체지방 감소 중 피부 탄력이 저하되는 것을 방지하고, 배변 역시 촉진하는 역할을 한다. In addition, the Rubies (Malus pumila Mill) apples are newly grown varieties bred by crossing the Japanese variety 'Alps Otome' with the 'Sansa' variety. When the dry extract is further included, it prevents deterioration of skin elasticity during body fat reduction due to excellent antioxidant activity, etc., and also promotes bowel movements.
본 발명에서 상기 갯끈풀 추출물, 루비에스 사과껍질 추출물의 추출방법은 제한하지 않으나, 시료에 5~20중량배의 물을 가하고, 20~100℃에서 5~20시간 추출, 여과, 농축 및 건조하는 정도면 족하다.In the present invention, the extraction method of the seaweed extract and rubies apple peel extract is not limited, but 5 to 20 times by weight of water is added to the sample, and extracted, filtered, concentrated and dried at 20 to 100° C. for 5 to 20 hours. That's enough.
또한, 본 발명의 건강기능식품은, 합다리나무 추출물 0.1~1중량%를 더 포함할 수 있다.In addition, the health functional food of the present invention may further include 0.1 to 1% by weight of the extract of Hapdari tree.
상기 합다리 나무(Meliosma oldhamii)의 추출물 역시 피부 탄력이 저하되는 것을 방지하며, 식욕을 억제하는 역할을 하는 것으로, 합다리 나무의 잎을 물 등의 용매로 추출하여 건조한 추출물을 사용한다. The extract of the Hapdari tree (Meliosma oldhamii) also prevents the deterioration of skin elasticity and serves to suppress appetite, and a dry extract is used by extracting the leaves of the Hapdari tree with a solvent such as water.
상기 합다리 나무의 추출물의 추출방법 역시 제한하지 않는바, 예시적으로 합다리 나무의 잎에 5~20중량배의 물을 가하고, 20~100℃에서 5~20시간 추출, 여과, 농축 및 건조하는 정도면 족하다.The extraction method of the extract of the Hapdari tree is also not limited, for example, 5 to 20 times by weight of water is added to the leaves of the Hapdari tree, and extraction, filtration, concentration and drying at 20 to 100° C. for 5 to 20 hours. That's enough.
이하, 실시예를 통해 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail through examples.
(실시예 1 내지 3)(Examples 1 to 3)
하기 표 1과 같은 비율로 각 성분을 혼합하였다.Each component was mixed in the same ratio as in Table 1 below.
(HCA 750mg)Garcinia Cambogia Extract (Water Soluble, Soluble)
(HCA 750mg)
상기 그린커피빈 추출물은 그린커피빈에 10중량배의 물을 가하고, 80℃에서 10시간 추출한 후, 여과, 농축 및 건조하여 분말화하여 제조하였으며, 상기 마테 추출물은 마테나무 잎의 건조물에 10중량배의 물을 가하고, 80℃에서 10시간 추출한 후, 여과, 농축 및 건조하여 분말화하여 제조하였으며, 상기 갯끈풀 추출물, 루비에스 사과껍질 추출물, 합다리나무 추출물은 갯끈풀 잎의 건조물, 루비에스 사과껍질 및 합다리나무 잎의 건조물 각각에 10중량배의 물을 가하고, 80℃에서 10시간 추출한 후, 여과, 농축 및 건조하여 분말화하여 제조하였다. 여기서 상기 각 분말의 입도는 100~300mesh 정도였다.The green coffee bean extract was prepared by adding 10 times by weight of water to green coffee beans, extracting at 80° C. for 10 hours, filtration, concentration, and drying to powder. Pear water was added, extracted at 80° C. for 10 hours, filtered, concentrated, and dried to be powdered, and the seaweed extract, rubies apple peel extract, and Hapdari tree extract were dried products of sea bass leaves, rubies apple. 10 times by weight of water was added to each of the dried skins of the bark and leaves of H. serrata, extracted at 80° C. for 10 hours, filtered, concentrated and dried to make a powder. Here, the particle size of each powder was about 100 to 300 mesh.
(시험예 1)(Test Example 1)
배변이 힘든 변비 환자 80명을 20명씩 네 그룹으로 나누고, 1그룹에는 상기 실시예 1을, 2그룹에는 실시예 2를, 3그룹에는 실시예 3을, 4그룹에는 대조구로서 시판되는 변비약을 제공하였다. 그리고 1, 2, 3그룹은 각 식품을 아침 식사 및 저녁 식사 30분 전에 각각 1포(4g)씩을 물 200ml과 함께 일주일간 섭취토록 하였으며, 4그룹은 변비약의 복용방법에 따라 일주일간 복용토록 하였다. 그리고 배변 횟수 증가 정도, 변의 무른 정도 개선, 변의 양 증가, 잔변감 개선, 배변 촉진의 효과에 대하여 설문을 실시하여, 그 결과를 하기 표 2에 나타내었다.Eighty constipated patients with difficult defecation were divided into four groups of 20 each, with Example 1 for group 1, Example 2 for group 2, Example 3 for group 3, and a commercially available laxative for group 4 as a control. did. In addition, groups 1, 2, and 3 were instructed to take 1 sachet (4 g) of each food 30 minutes before breakfast and dinner together with 200 ml of water for a week, and group 4 was instructed to take it for a week according to the method of taking laxatives. . And the degree of increase in the frequency of defecation, improvement in the softness of the stool, increase in the amount of stool, improvement in the feeling of feces, and the effect of facilitating defecation were conducted, and the results are shown in Table 2 below.
(명)increase in the frequency of bowel movements
(number of people)
(명)improvement of stool softness
(number of people)
(명)increased amount of stool
(number of people)
(명) improvement of feeling
(number of people)
(명)facilitation of defecation
(number of people)
4 효과 많음, 5: 효과 매우 많음1: No effect at all, 2: Some effect, 3: Moderate effect,
4 a lot of effect, 5: a lot of effect
상기 표 2에서 확인할 수 있는 바와 같이, 본 발명의 실시예 1 내지 3은 모두 대조구에 비하여 우수한 배변 횟수 증가, 변의 무른 정도 개선, 변의 양 증가, 잔변감 개선 및 배변 촉진의 효과가 있음을 확인하였다.As can be seen in Table 2, Examples 1 to 3 of the present invention all have the effect of increasing the number of bowel movements, improving the softness of the stool, increasing the amount of stool, improving the feeling of defecation, and promoting defecation compared to the control group.
(시험예 2)(Test Example 2)
상기 실시예 1 내지 3에 대해 맛, 향, 전체적인 기호도와 같은 관능평가를 실시하였다. 상기의 관능평가는 식품관련분야에서 3년 이상 경험을 가진 20명(남녀 각각 10명)으로 하여 5점 척도법으로 측정하였다. 그리고 그 결과의 평균치를 소수점 둘째 자리에서 반올림하여 하기 표 3에 나타내었다.For Examples 1 to 3, sensory evaluations such as taste, aroma, and overall preference were performed. The above sensory evaluation was measured by a 5-point scale method with 20 people (10 males and females each) who had more than 3 years of experience in the food-related field. And the average value of the result was rounded to the second decimal place and shown in Table 3 below.
상기 표 3에서 확인할 수 있는 것과 같이, 본 발명의 실시예 1 내지 3은 관능적 기호도 역시 우수함을 확인하였다. As can be seen in Table 3, Examples 1 to 3 of the present invention confirmed that the sensory preference is also excellent.
(시험예 3)(Test Example 3)
복부 비만이 있는 성인 남녀 30명을 10명씩 세 그룹으로 나누고, 1그룹에는 상기 실시예 1을, 2그룹에는 실시예 2를, 3그룹에는 실시예 3을 제공하였다. 그리고 1, 2, 3그룹은 각 식품을 아침 식사 및 저녁 식사 30분 전에 각각 1포(4g)씩 물 200ml과 함께 8주간 섭취토록 하였다.Thirty adult males and females with abdominal obesity were divided into three groups of 10 people each. Example 1 was provided to group 1, Example 2 to group 2, and Example 3 to group 3. In addition, groups 1, 2, and 3 were instructed to ingest each food 30 minutes before breakfast and dinner together with 1 sachet (4 g) of 200 ml of water for 8 weeks.
그리고 섭취 전, 후의 체중, 체지방율, 내장지방면적 변화에 미치는 영향을 평가하였다. 상기 평가는 InBody로 측정하였으며, 측정 당일 동일한 복장을 입도록 하였다. 그 결과를 10명의 평균치로 하기 표 4에 나타내었다. And the effect on the change of body weight, body fat percentage, and visceral fat area before and after intake was evaluated. The evaluation was measured by InBody, and the same clothes were worn on the day of the measurement. The results are shown in Table 4 below as an average of 10 participants.
상기 표 4에서 확인할 수 있는 바와 같이, 실시예 1 내지 3 모두 체중, 체지방량 등이 감소하는 것을 확인할 수 있었으며, 내장 지방의 감소량에는 더욱 큰 효과가 있음을 확인할 수 있었다.As can be seen in Table 4, it was confirmed that in Examples 1 to 3, body weight, body fat, and the like decreased, and it was confirmed that there was a greater effect in reducing the amount of visceral fat.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당 업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As described above in detail a specific part of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (4)
Indigestion maltodextrin, garcinia cambogia extract, coffee bean powder, polydextrose, crystalline glucose, fructose, silicon dioxide, enzyme-treated stevia, green coffee bean extract, and mate extract, characterized in that it contains defecation induction and diet health functional food .
상기 가르시니아 캄보지아 추출물 10~20중량%, 원두커피분말 15~25중량%, 폴리덱스트로스 8~12중량%, 결정포도당 8~12중량%, 결정과당 3~7중량%, 이산화규소 1.5~2중량%, 효소처리스테비아 0.1~1중량%, 그린커피빈 추출물 0.01~0.5중량%, 마테 추출물 0.01~0.5중량% 및 잔부의 난소화성 말토덱스트린을 포함하는 것을 특징으로 하는 배변유도 및 다이어트용 건강기능식품.
According to claim 1,
The garcinia cambogia extract 10-20% by weight, coffee bean powder 15-25% by weight, polydextrose 8-12% by weight, crystalline glucose 8-12% by weight, fructose 3-7% by weight, silicon dioxide 1.5-2% by weight, Enzyme-treated stevia 0.1 to 1% by weight, green coffee bean extract 0.01 to 0.5% by weight, mate extract 0.01 to 0.5% by weight, and the balance indigestible maltodextrin, defecation induction and diet health functional food, characterized in that it contains.
갯끈풀 추출물 0.1~1중량% 및 루비에스 사과껍질 추출물 0.1~1중량%를 더 포함하는 것을 특징으로 하는 배변유도 및 다이어트용 건강기능식품.
3. The method of claim 2,
A health functional food for bowel induction and diet, characterized in that it further comprises 0.1 to 1% by weight of seaweed extract and 0.1 to 1% by weight of rubies apple peel extract.
합다리나무 추출물 0.1~1중량%를 더 포함하는 것을 특징으로 하는 배변유도 및 다이어트용 건강기능식품.4. The method of claim 3,
Health functional food for defecation induction and diet, characterized in that it further comprises 0.1 to 1% by weight of Hapdari tree extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200018903A KR20210104952A (en) | 2020-02-17 | 2020-02-17 | Functional health food for defecaation inducement and diet |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200018903A KR20210104952A (en) | 2020-02-17 | 2020-02-17 | Functional health food for defecaation inducement and diet |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210104952A true KR20210104952A (en) | 2021-08-26 |
Family
ID=77465447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200018903A KR20210104952A (en) | 2020-02-17 | 2020-02-17 | Functional health food for defecaation inducement and diet |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210104952A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102438059B1 (en) * | 2022-04-04 | 2022-09-01 | 주식회사 위드랩스 | Composition for weight control containing garcinia cambogia extract and enzyme |
KR102476982B1 (en) * | 2022-04-04 | 2022-12-14 | 주식회사 위드랩스 | The composition for the weight control including the grains fermentation product and garcinia cambogia |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101256841B1 (en) | 2011-11-15 | 2013-04-23 | 노길형 | The manufacturing method of enzyme food to be contained kimchi component |
KR101487769B1 (en) | 2014-08-19 | 2015-01-29 | 인성제약(주) | Food Composition for Bowel Movement Promotion and Diet using Aspergillus oryzae |
KR101721145B1 (en) | 2015-07-29 | 2017-03-29 | 제너럴바이오(주) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement |
-
2020
- 2020-02-17 KR KR1020200018903A patent/KR20210104952A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101256841B1 (en) | 2011-11-15 | 2013-04-23 | 노길형 | The manufacturing method of enzyme food to be contained kimchi component |
KR101487769B1 (en) | 2014-08-19 | 2015-01-29 | 인성제약(주) | Food Composition for Bowel Movement Promotion and Diet using Aspergillus oryzae |
KR101721145B1 (en) | 2015-07-29 | 2017-03-29 | 제너럴바이오(주) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102438059B1 (en) * | 2022-04-04 | 2022-09-01 | 주식회사 위드랩스 | Composition for weight control containing garcinia cambogia extract and enzyme |
KR102476982B1 (en) * | 2022-04-04 | 2022-12-14 | 주식회사 위드랩스 | The composition for the weight control including the grains fermentation product and garcinia cambogia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101744170B (en) | Tartary buckwheat eight ingredient porridge suitable for patients with diabetes and preparing method thereof | |
US20030064937A1 (en) | Composition for reducing appetite in mammals | |
KR102295696B1 (en) | Oral solution powder composition for fatigue reduction and method of preparing the same | |
JP2008094754A (en) | Nutrient composition for diabetes or blood sugar control | |
CN102224891A (en) | Sugar alcohol honey apple jam and preparation method thereof | |
CN102038260B (en) | Chinese medicinal alcoholism relieving health-care beverage and preparation method thereof | |
CN104286273A (en) | Application of dendrobium candidum and tea leaf product thereof | |
Yampolsky et al. | Apricot (lat. Prunus armeniaca Lin.) | |
KR20210104952A (en) | Functional health food for defecaation inducement and diet | |
US20140127297A1 (en) | Nutraceutical composition for limiting the absorption of dietary lipids and for inducing weight loss, comprising, as active agent, at least one extract of carrot | |
CN105558198A (en) | Health-care tea capable of reducing blood sugar and preparation method of health-care tea | |
KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
CN105029553A (en) | Fruit juice-egg-calcium traditional Chinese medicine health beverage and preparation method thereof | |
KR101721145B1 (en) | - Food composition including -Carnitine Magnesium Citrate for diet and promoting bowel movement | |
KR101177888B1 (en) | Composition for Relieving and Preventing Hangover | |
CN105249475A (en) | Health care alga agar-agar jelly and preparation method of health care alga agar-agar jelly | |
KR101237215B1 (en) | Phamaceutical composition for prevention or treatment of enteritis | |
EP1693084A1 (en) | Alga extract and lipase inhibitor containing the same | |
KR20180056199A (en) | Manufacturing method of gum for diet containing Moringa Oleifera extract | |
KR101391647B1 (en) | Anti obesity composition | |
KR20180002157A (en) | A composition for removing hangover comprising an extract of Cinnamomum cassia Presl and cinnamomi petiole | |
JP4669077B1 (en) | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient | |
JP2009034017A (en) | Diet food | |
KR102609638B1 (en) | Composition comprising underia pinnatifida sporophyll hot-water extract for improving gut microbiome | |
KR20200130030A (en) | Methods for the manufacture of yogurt products with the effect of blood sugar control on diabetics and potential patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |